Compare Panacea Biotech with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SUN PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SUN PHARMA PANACEA BIOTECH/
SUN PHARMA
 
P/E (TTM) x 15.8 84.7 18.7% View Chart
P/BV x 6.2 3.6 170.8% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   SUN PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
SUN PHARMA
Mar-20
PANACEA BIOTECH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs354484 73.0%   
Low Rs138315 43.8%   
Sales per share (Unadj.) Rs74.6136.9 54.5%  
Earnings per share (Unadj.) Rs6.717.5 38.3%  
Cash flow per share (Unadj.) Rs15.526.0 59.6%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs57.2188.7 30.3%  
Shares outstanding (eoy) m61.252,399.26 2.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.32.9 112.9%   
Avg P/E ratio x36.822.9 160.8%  
P/CF ratio (eoy) x15.915.4 103.3%  
Price / Book Value ratio x4.32.1 202.9%  
Dividend payout %022.9 0.0%   
Avg Mkt Cap Rs m15,061958,864 1.6%   
No. of employees `0002.317.8 13.0%   
Total wages/salary Rs m1,47163,624 2.3%   
Avg. sales/employee Rs Th1,973.618,490.6 10.7%   
Avg. wages/employee Rs Th635.63,582.6 17.7%   
Avg. net profit/employee Rs Th176.82,357.6 7.5%   
INCOME DATA
Net Sales Rs m4,567328,375 1.4%  
Other income Rs m456,360 0.7%   
Total revenues Rs m4,612334,735 1.4%   
Gross profit Rs m2,03069,898 2.9%  
Depreciation Rs m54020,528 2.6%   
Interest Rs m1,0483,027 34.6%   
Profit before tax Rs m48652,702 0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m778,228 0.9%   
Profit after tax Rs m40941,868 1.0%  
Gross profit margin %44.421.3 208.8%  
Effective tax rate %15.915.6 101.6%   
Net profit margin %9.012.8 70.3%  
BALANCE SHEET DATA
Current assets Rs m2,415316,542 0.8%   
Current liabilities Rs m9,077157,064 5.8%   
Net working cap to sales %-145.948.6 -300.4%  
Current ratio x0.32.0 13.2%  
Inventory Days Days6588 74.3%  
Debtors Days Days71105 67.7%  
Net fixed assets Rs m8,333243,102 3.4%   
Share capital Rs m612,399 2.6%   
"Free" reserves Rs m3,443450,245 0.8%   
Net worth Rs m3,504452,645 0.8%   
Long term debt Rs m46120,289 2.3%   
Total assets Rs m13,755682,525 2.0%  
Interest coverage x1.518.4 8.0%   
Debt to equity ratio x0.10 293.6%  
Sales to assets ratio x0.30.5 69.0%   
Return on assets %10.66.6 161.1%  
Return on equity %11.79.2 126.2%  
Return on capital %38.711.2 344.5%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,20374,219 1.6%   
Fx outflow Rs m46727,964 1.7%   
Net fx Rs m73646,255 1.6%   
CASH FLOW
From Operations Rs m1,04965,548 1.6%  
From Investments Rs m-54-25,888 0.2%  
From Financial Activity Rs m-1,011-57,151 1.8%  
Net Cashflow Rs m-20-13,857 0.1%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 5.1 11.7%  
FIIs % 1.3 23.0 5.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 8.3 284.3%  
Shareholders   10,259 133,026 7.7%  
Pledged promoter(s) holding % 35.1 0.5 6,617.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DR. DATSONS LABS  BIOCON   J.B.CHEMICALS  JUBILANT PHARMOVA   AJANTA PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Tata Consumer March Quarter Results, M&M's Advanced Design Centre, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended higher on Friday. Benchmark indices edged higher tracking gains in index majors HDFC twins and positive cues from global markets.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


May 7, 2021 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS